Previous 10 | Next 10 |
Windtree TherapeuticS press release (NASDAQ:WINT): Q1 GAAP EPS of -$0.29 beats by $0.01. Cash and cash equivalents of $15.5M is sufficient to provide runway into the first quarter of 2023. For further details see: Windtree TherapeuticS GAAP EPS of -$0.29 beats by $0.01
Announced positive topline results from Phase 2 SEISMiC study of istaroxime in early cardiogenic shock Late-breaker presentation of additional SEISMiC study results at the European Society of Cardiology (ESC) Heart Failure Conference. Management to host investor ...
Gainers: Cyngn (CYN) +70%. Sky Harbour Group (SKYH) +28%. Redbox Entertainment (RDBX) +25%. Wrap Technologies (WRAP) +18%. Inozyme Pharma (INZY) +16%. MedAvail Holdings (MDVL) +14%. Red Cat Holdings (OTCQB:RCAT) +13%. Pulse Biosciences (PLSE) +12%. United Airlines Holdings (UAL) +11%. Alpha T...
Gainers: Inozyme Pharma (INZY) +15%. Clarus Therapeutics (CRXT) +10%. MedAvail (MDVL) +5%. Syros Pharmaceuticals (SYRS) +5%. Magenta Therapeutics (MGTA) +4%. Losers: AlloVir (ALVR) -10%. Rite Aid (RAD) -9%. Windtree Therapeutics (WINT) -7...
WARRINGTON, Pa., April 20, 2022 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today announced a late-breaker presentation at the upcoming Euro...
Understanding Penny Stocks And 3 Hot Ones to Watch Now Trading penny stocks can have a lot of intricacies that inexperienced investors don’t understand. However, if you take the time to learn about this type of trading, it can be a very lucrative investment. With penny stocks ...
Windtree Therapeutics (NASDAQ:WINT) has added ~33% in the pre-market Wednesday after the clinical-stage biotech reported topline data from its SEISMiC Phase 2 study for istaroxime in early cardiogenic shock. According to the company, the 60-patient global trial met the primary endpo...
WARRINGTON, Pa., April 20, 2022 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today announced positive primary results with istaroxime in rapi...
WARRINGTON, Pa., March 31, 2022 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today announced that Craig Fraser, President and Chief Executive Officer...
Windtree TherapeuticS press release (NASDAQ:WINT): FY GAAP EPS of -$2.73 misses by $0.17. As of December 31, 2021, the Company reported cash and cash equivalents of $22.3 million. For further details see: Windtree TherapeuticS GAAP EPS of -$2.73 misses by $0.17
News, Short Squeeze, Breakout and More Instantly...
Windtree Therapeutics Inc. Company Name:
WINT Stock Symbol:
OTCMKTS Market:
Windtree Therapeutics Inc. Website:
$12.9 Million Transaction Includes Approximately $3.4 Million of New Funding and a $9.5 Million Full Cancellation of Outstanding Senior Notes and Extinguishment of Series B Preferred Shares The Company Also Established a $35 Million Equity Line of Credit WA...
Windtree Therapeutics Inc. (WINT) is expected to report for Q1 2024 CohBar Inc. (CWBR) is expected to report for Q1 2024 hopTo Inc (HPTO) is expected to report for Q1 2024 Bitech Technologies Corporation (BTTC) is expected to report for Q1 2024 Roadzen Inc. (RDZN) is expected to r...
Gelesis Holdings, Inc. (GLSHQ) is expected to report for Q1 2024 EVmo Inc (YAYO) is expected to report for Q1 2024 Chiba Bank Ltd. ADR (CHBAY) is expected to report for Q4 2024 Spark Networks SE (LOVLQ) is expected to report for Q1 2024 ToughBuilt Industries Inc. (TBLT) is expecte...